Could lowering insulin help fight fatty liver? new study tests diazoxide
NCT ID NCT07403604
First seen Feb 16, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-stage trial is testing whether a one-week course of diazoxide can reduce the production of new fat in the liver. The study involves 25 adults with obesity, insulin resistance, and fatty liver disease. Participants will take either the drug or a placebo and undergo blood tests and insulin suppression tests to measure changes in liver fat production and other metabolic markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
diazoxide (oral suspension)
What this could lead to
If successful, this study could point toward a new way to treat fatty liver disease by lowering insulin levels.
What could go wrong
This is a very early phase 1 trial with only 25 participants, so results may not apply to everyone. The drug may not reduce liver fat or could cause side effects like fluid retention or low blood sugar.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.